Tags

Type your tag names separated by a space and hit enter

Amantadine versus methylphenidate in children and adolescents with attention deficit/hyperactivity disorder: a randomized, double-blind trial.
Hum Psychopharmacol. 2010 Nov; 25(7-8):560-5.HP

Abstract

OBJECTIVE

The aim of the present study was to further evaluate, under double blind and controlled conditions, the efficacy of amantadine for attention-deficit/hyperactivity disorder (ADHD) in children and adolescents as compared to methylphenidate.

METHODS

This was a 6-week randomized clinical trial. Forty patients (28 boys and 12 girls) with a DSM-IV-TR diagnosis of ADHD were the study population of this trial. All study subjects were randomly assigned to receive the treatment using capsule of amantadine at a dose of 100-150 mg/day depending on weight (100 mg/day for <30 kg and 150 mg/day for >30 kg) or methylphenidate at a dose of 20-30 mg/day for a 6-week double blind, randomized clinical trial. The principal measure of outcome was the Teacher and Parent Attention deficit/hyperactivity disorder Rating Scale-IV.

RESULTS

No significant differences were observed between the two groups on the Parent and Teacher Rating Scale scores (df = 1; F = 0.02; p = 0.86 and df = 1; F = 0.01; p = 0.89, respectively). Side effects of decreased appetite and restlessness were observed more frequently in the methylphenidate group.

CONCLUSION

The results of this study indicate that amantadine significantly improved symptoms of ADHD and was well tolerated and it may be beneficial in the treatment of children with ADHD. Nevertheless, the present results do not constitute proof of efficacy.

Authors+Show Affiliations

Psychiatric Research Centre, Roozbeh Hospital, Tehran University of Medical Sciences, Tehran, Iran.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

21312290

Citation

Mohammadi, Mohammad-Reza, et al. "Amantadine Versus Methylphenidate in Children and Adolescents With Attention Deficit/hyperactivity Disorder: a Randomized, Double-blind Trial." Human Psychopharmacology, vol. 25, no. 7-8, 2010, pp. 560-5.
Mohammadi MR, Kazemi MR, Zia E, et al. Amantadine versus methylphenidate in children and adolescents with attention deficit/hyperactivity disorder: a randomized, double-blind trial. Hum Psychopharmacol. 2010;25(7-8):560-5.
Mohammadi, M. R., Kazemi, M. R., Zia, E., Rezazadeh, S. A., Tabrizi, M., & Akhondzadeh, S. (2010). Amantadine versus methylphenidate in children and adolescents with attention deficit/hyperactivity disorder: a randomized, double-blind trial. Human Psychopharmacology, 25(7-8), 560-5. https://doi.org/10.1002/hup.1154
Mohammadi MR, et al. Amantadine Versus Methylphenidate in Children and Adolescents With Attention Deficit/hyperactivity Disorder: a Randomized, Double-blind Trial. Hum Psychopharmacol. 2010;25(7-8):560-5. PubMed PMID: 21312290.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Amantadine versus methylphenidate in children and adolescents with attention deficit/hyperactivity disorder: a randomized, double-blind trial. AU - Mohammadi,Mohammad-Reza, AU - Kazemi,Mohammad-Reza, AU - Zia,Ebtehal, AU - Rezazadeh,Shams-Ali, AU - Tabrizi,Mina, AU - Akhondzadeh,Shahin, Y1 - 2010/12/08/ PY - 2010/08/11/received PY - 2010/10/28/accepted PY - 2011/2/12/entrez PY - 2011/2/12/pubmed PY - 2011/8/27/medline SP - 560 EP - 5 JF - Human psychopharmacology JO - Hum Psychopharmacol VL - 25 IS - 7-8 N2 - OBJECTIVE: The aim of the present study was to further evaluate, under double blind and controlled conditions, the efficacy of amantadine for attention-deficit/hyperactivity disorder (ADHD) in children and adolescents as compared to methylphenidate. METHODS: This was a 6-week randomized clinical trial. Forty patients (28 boys and 12 girls) with a DSM-IV-TR diagnosis of ADHD were the study population of this trial. All study subjects were randomly assigned to receive the treatment using capsule of amantadine at a dose of 100-150 mg/day depending on weight (100 mg/day for <30 kg and 150 mg/day for >30 kg) or methylphenidate at a dose of 20-30 mg/day for a 6-week double blind, randomized clinical trial. The principal measure of outcome was the Teacher and Parent Attention deficit/hyperactivity disorder Rating Scale-IV. RESULTS: No significant differences were observed between the two groups on the Parent and Teacher Rating Scale scores (df = 1; F = 0.02; p = 0.86 and df = 1; F = 0.01; p = 0.89, respectively). Side effects of decreased appetite and restlessness were observed more frequently in the methylphenidate group. CONCLUSION: The results of this study indicate that amantadine significantly improved symptoms of ADHD and was well tolerated and it may be beneficial in the treatment of children with ADHD. Nevertheless, the present results do not constitute proof of efficacy. SN - 1099-1077 UR - https://www.unboundmedicine.com/medline/citation/21312290/Amantadine_versus_methylphenidate_in_children_and_adolescents_with_attention_deficit/hyperactivity_disorder:_a_randomized_double_blind_trial_ L2 - https://doi.org/10.1002/hup.1154 DB - PRIME DP - Unbound Medicine ER -